Next Phase Newsletter

A strategic capital group within a large company is focused on venture and growth stage investments in several verticals including healthcare, IT and energy. The group will make investments from $5M – $30M and is very flexible with structure and size, with approximately 80% of investments in the form of equity and the other 20% in debt. The group will both lead or co-invest and typically seeks board representation although it is not a requirement. The group is focused on companies in the United States, but may look at some international opportunities in select geographies.

The firm is interested in medical devices, healthcare services, digital health, and biopharma and the group is looking for derisked opportunities in these areas. In the medical device space, the group is interested in devices that have achieved FDA approval and have reimbursement established. Digital health/healthcare IT companies should have commercial traction and a minimum of 10-20 paying customers. The group is looking for healthcare services companies that have proven their business model and are in need of growth capital. In the biopharma space, the group avoids opportunities with binary scientific, development, or clinical risk and is interested in areas such as specialty pharma, outsourced services, platform technologies, etc.

The firm places a large emphasis on high quality management teams and will work with companies with an incomplete management team as long as the key members of management are in place and have significant experience/expertise in the area they are pursuing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical company based in China is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm currently manages two funds with over $200 million AUM and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare and life sciences investments, while the rest of the fund will focus on investing in electronic materials and aluminum business. On average, the size of investment is $10M, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can invest in a broad variety of types and transaction structures including growth capital, buyouts, late-stage developments (with proof of concept), and recapitalizations. The firm looks for companies located around the globe, with a preference in the US, Europe, and Japan.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm is open to all kinds of sectors and indications with preferences in antivirus, oncology, neurosciences, and diabetes. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase I, and from phase III to on-the-market; while middle stage products might be a less focus. Regarding medical devices and diagnostics, the firm will invest at any stage of development. The firm is willing to consider companies targeting orphan indications.

The firm can invest in both private and public companies. The firm is willing to both lead and co-invest in companies located around the globe, while co-invest is their sweet spot. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA based medical technology venture firm founded in 2013 makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm founded in 2015 is actively supporting new healthcare companies in the USA and Canada. The firm is partnering with a New York-based firm to fund companies and assist those companies in scaling. The firm typically invests $250,000-$1.5 million, and while the firm focuses on companies interested in a “soft landing” in Western New York, the firm has the capacity to invest elsewhere as well.

The firm focuses on healthcare solutions that include a software component. Areas of interest include remote sensing, healthcare in the cloud, assistive devices, and remote sensing devices (e.g. Health IT).

The firm focuses on companies that have the capacity to become US government contractors. The firm supports their portfolio companies in bidding for contracts, and is able to work with both US and Canadian companies interested in becoming listed on the GSA Schedule.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with headquarters in Taiwan also has additional venture partners based in USA and multiple Asian countries. Based on National Development Fund in Taiwan, Taiwan Government matched 30% of the fund formed between local and international investors. The firm has over $100M AUM and its initial size of investment is in $1-6M range. However, the firm has the capacity to invest more in companies they identify as a strong fit. The firm is looking for companies globally but would prefer companies that have a Taiwan angle.

The firm is an opportunistic investor that currently considering Therapeutics, Medical Devices, Diagnostics, Biotechnology R&D, and Healthcare IT companies. The firm is open to many sectors in therapeutics but would prefer phases that past pre-clinical. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled device. The firm invest in any phases in medical devices and diagnostics especially in clinical. The firm looks into any indications except orphan disease.

The firm currently will invest in privately held companies only. The firm has no specific requirements for management team. The firm can participate as either lead or co-investor and generally requests a board seat or board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and developer of medical technologies is headquartered in Taipei, Taiwan with a USA subsidiary. With vertical integration of experienced medical professionals, talented engineers, and international infrastructure, the firm is dedicated to developing high value and high impact medical devices. The firm looks for new in-licensing or investment opportunities in cutting-edge medical device innovations from North America, Asia, and Europe, with no set cap on investment size.

Focusing on minimally invasive surgical devices and healthcare information technologies, the firm invests in companies at any stage of development, from ideation, early product design, prototyping, preclinical testing, clinical trials to commercialization. The firm prefers disease states with sizable patient population, including but not limited to cardiovascular or peripheral vascular disease, orthopedics, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery.

The firm is looking for collaborations with competent entrepreneurs, physicians, companies and investors and willing to lead and co-invest in med-tech companies to develop novel solutions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2007 with multiple offices globally has deep business expertise across USA and Asia and works with a close network of over 30 large Asian companies, which enables the firm to help portfolio companies beyond capital investment. The firm focuses on Series A financing rounds primarily in US startups with initial investment sizes ranging between $3-5M (USD) but will selectively participate in Seed and Series B rounds as well. The firm seeks to make 5-7 investments per year, and will selectively consider investment opportunities globally.

The firm invests in a wide range of technology subsectors, including consumer tech and enterprise solutions. In the life sciences/healthcare space, the firm is most interested in health IT/digital health companies including non-invasive health devices, data informatics and SaaS healthcare solutions. The firm is indication agnostic.

The firm seeks to invest in companies with strong potential in the US and Asia markets that could benefit from the firm’s value add-on. The firm prefers to act as the lead investor and have board representation, but is open to co-investing in select cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.